Anesiva (ANSV) Names Kranda President/CEO
Anesiva, Inc. (Nasdaq: ANSV) today announced that its Board has appointed Michael Kranda as President and CEO, effective June 16. Mr. Kranda succeeds John P. McLaughlin, who resigned as CEO and member of the Anesiva board to pursue other business interests, while remaining a consultant to the company.
Anesiva, Inc., a biopharmaceutical company, engages in the development and commercialization of novel therapeutic treatments for pain management.
Anesiva, Inc., a biopharmaceutical company, engages in the development and commercialization of novel therapeutic treatments for pain management.
You May Also Be Interested In
- Rosetta Genomics (ROSG) Names New CFO
- Green Mountain (GMCR) Director Douglas Daft Resigns, Co. Reduces Size of Board to Eight
- Canaccord Genuity Morning Coffee on Cree (CREE) and Extreme Networks (EXTR): Shedding Some Light On The Situation
Create E-mail Alert Related Categories
Management ChangesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
